Financial Performance - The company's revenue for the year ended December 31, 2025, was SGD 18,586,000, representing a 77.8% increase from SGD 10,459,000 in 2024[4] - Gross profit for the same period was SGD 3,318,000, compared to SGD 228,000 in 2024, indicating a significant improvement[4] - The company reported a net loss of SGD 612,000 for 2025, a reduction from a net loss of SGD 2,631,000 in 2024, reflecting a 76.8% decrease in losses[5] - Total segment revenue for the year ending December 31, 2025, is SGD 18,586,000, with the medical components segment contributing SGD 10,580,000[23] - The medical components segment reported a profit of SGD 2,366,000, while the total segment profit was SGD 3,312,000[23] - The company reported a loss before tax of 600 thousand Singapore dollars for 2025, compared to a loss of 2,785 thousand Singapore dollars in 2024, indicating an improvement in financial performance[34] - The overall gross profit increased from approximately SGD 0.2 million in FY2024 to approximately SGD 3.3 million in FY2025, with the gross profit margin rising from a loss margin of about 2.2% to a profit margin of approximately 17.9%[51] - The net loss for FY2025 was approximately SGD 0.6 million, significantly reduced from a loss of SGD 2.6 million in FY2024[47] Assets and Liabilities - Total assets decreased to SGD 6,407,000 in 2025 from SGD 6,491,000 in 2024, while total liabilities increased to SGD 6,048,000 from SGD 3,550,000[6] - The company's equity attributable to owners decreased to SGD 1,524,000 in 2025 from SGD 2,141,000 in 2024, reflecting a decline in shareholder value[7] - Current liabilities due within one year as of December 31, 2025, amount to approximately SGD 6,048,000, while cash and bank balances are around SGD 1,190,000[11] - Total liabilities rose to 7,414 thousand Singapore dollars in 2025 from 6,627 thousand Singapore dollars in 2024, marking an increase of 11.9%[26] Cash Flow and Liquidity - The company's cash and cash equivalents decreased to SGD 1,190,000 in 2025 from SGD 1,779,000 in 2024, indicating a liquidity challenge[6] - The current ratio decreased to approximately 1.1 times as of December 31, 2025, from 1.8 times in FY2024, mainly due to a reduction in cash and cash equivalents and an increase in borrowings[61] - Cash and cash equivalents were approximately SGD 1.2 million as of December 31, 2025, down from SGD 1.8 million in FY2024[61] Borrowings and Financial Costs - The company incurred finance costs of SGD 278,000 in 2025, up from SGD 167,000 in 2024, indicating increased borrowing costs[4] - The company has a significant amount of borrowings, with SGD 1,084,000 in loans in 2025 compared to SGD 531,000 in 2024, indicating increased leverage[6] - Financial costs rose from approximately SGD 0.2 million in FY2024 to about SGD 0.3 million in FY2025, attributed to accrued interest from a shareholder loan[60] Revenue Sources and Business Operations - The company is primarily engaged in the manufacturing and sale of disposable medical devices and is exploring data solutions and services in mainland China[8] - The company has diversified its revenue sources by expanding into data solutions and hotel-related businesses, contributing to the overall revenue growth[47] - Major customer A contributed 10,589 thousand Singapore dollars to total revenue in 2025, up from 7,859 thousand Singapore dollars in 2024, while customer B's contribution was not applicable in 2025[27] - The geographical distribution of external customer revenue showed that mainland China contributed 6,552 thousand Singapore dollars in 2025, a substantial increase from 841 thousand Singapore dollars in 2024[28] Expenses and Other Income - Research and development expenses decreased to 403 thousand Singapore dollars in 2025 from 559 thousand Singapore dollars in 2024, a reduction of 27.9%[31] - Other income decreased by approximately SGD 0.5 million or 62.5% from about SGD 0.8 million in FY2024 to about SGD 0.3 million in FY2025, primarily due to a reduction in government grants[52] - The company recorded a net other loss of approximately SGD 0.2 million in FY2025, compared to a net other income of approximately SGD 0.2 million in FY2024, mainly due to foreign exchange losses[53] - Administrative expenses increased by approximately SGD 0.5 million or 18.5% from about SGD 2.7 million in FY2024 to approximately SGD 3.2 million in FY2025, driven by increased professional service costs due to business expansion[58][59] Shareholder Information and Corporate Governance - The board did not recommend the distribution of a final dividend for the year ending December 31, 2025[76] - As of December 31, 2025, Mr. Pan Ruihe holds 33,832,000 shares, representing 4.13% of the company's total shares[77] - Mr. Xie Jianlong owns 61,612,000 shares, accounting for 7.53% of the company's total shares, while Ms. Wu Haiyan holds 52,694,000 shares, representing 6.44%[79] - The company has adhered to the corporate governance code as per GEM listing rules, except for the separation of roles between the Chairman and CEO, which is currently held by Mr. Pan[88] - All directors confirmed compliance with the trading standards for securities transactions during the fiscal year 2025, with no known non-compliance events[89] Audit and Compliance - The auditor, Zhongzheng Tianheng CPA, will present a resolution for reappointment at the upcoming annual general meeting[91] - The auditor has verified that the financial figures in the performance announcement are consistent with the audited financial statements for the year ending December 31, 2025[92] - The audit committee, consisting of three independent non-executive directors, has reviewed the audited financial information and confirmed compliance with applicable accounting standards and GEM listing rules[93]
加和国际控股(08513) - 2025 - 年度业绩